Compare DexCom, Inc. (DXCM) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Innodata Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Innodata Inc trades at $62.04 (market cap $2.10B). The key difference: DexCom, Inc. is far larger — about 15.2× Innodata Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Innodata Inc for 19 Days on average.
| DXCM | INOD | |
|---|---|---|
Market Cap | $31.86B | $2.10B |
Volume | 3,607,070 | 989,493 |
Sector | Health | Technology |
52-Week High | $92.34 | $121.50 |
52-Week Low | $54.84 | $34.45 |
Typical Hold Time | 62 Days | 19 Days |
Enterprise Value | $31.32B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
INOD trades at $61.20, down 3.49% today, amid a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations with Q1 2026 EPS of $0.42 versus $0.13 expected, driven by robust revenue growth and expanding profit margins. Recent developments include the opening of a motion-capture AI lab and strategic board appointments, positioning the company for continued AI infrastructure growth.
The outlook remains positive given strong earnings momentum and AI sector tailwinds, though premium valuation metrics (P/E 47.43) and technical weakness present near-term risks. Analyst consensus is bullish with 67% buy ratings, but investors should monitor customer concentration and competitive pressures in the rapidly evolving AI services market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
